Global Oncology Biosimilars Market Research Report 2016\

The global oncology biosimilars market will witness substantial growth over the forecast period and is expected to grow at very impressive CAGR during the forecast period. The increasing need for cost-effective treatment methodologies will aid in the stable growth of this market during the forecast period. The high cost of branded biologic oncological drugs will force patients to shift toward biosimilars as they are highly cost-effective. Since biosimilars cost 10%-30% lesser than their parent counterparts, there is the presence of unmet medical needs for such products. This allows domestic manufacturers to market generic versions of the biologic compounds at a lower price, which in turn results in market growth.
Cancer represents a massive burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of several cancer therapeutics has allowed the entry of biosimilars, which are being incorporated into oncology treatment practices. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes. The market offers huge growth opportunities for vendors because of the growing incidence of cancer. The clinical pipeline for cancer biosimilars is vast, featuring candidates in different stages of development. Around 30% of all the biosimilars that are awaiting the US FDA’s approval are monoclonal antibodies, including biosimilars of Avastin, MabThera, and Herceptin.
Factors like the arrival of new biosimilars to drive market growth during the forecast period. Unlike generic drugs, which have APIs that are identical to original drugs, biosimilars are similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. Since they are less expensive than biologics, patients will be able to afford and access biosimilars more easily than biologics. Rise in number of patent expiries, increase in prevalence of cancer, growing aging population, promising drug pipeline, need for cost-effective treatment, favorable government regulations are some of the key drivers promoting the growth of oncology biosimilars market.

The Global Oncology Biosimilars Market Research Report 2016 is a valuable source of insightful data for business strategists. It provides the Oncology Biosimilars industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Oncology Biosimilars market study provides comprehensive data which enhances the understanding, scope and application of this report.
This report provides comprehensive analysis of
Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technological breakthroughs

Global Oncology Biosimilars Market: Regional Segment Analysis
North America
Europe
China
Japan
Southeast Asia
India

The Major players reported in the market include:
Biocon
Amgen
Celltrion
Hospira
Biogen
Mylan
Pfizer
Dr. Reddy's Laboratories
Roche
GlaxoSmithKline (GSK)
Merck
Sanofi and Sandoz.
...

Global Oncology Biosimilars Market: Product Segment Analysis
Type I
Type II
Type III

Global Oncology Biosimilars Market: Application Segment Analysis
Application I
Application II
Application III

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

Frequently Asked Questions